BMS-986141 for Prevention of Recurrent Brain Infarction

Phase 2, randomised, double-blind trial of bms-986141 in ischemic stroke and Transient Ischemic Attack (TIA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28 and Percentage of Participants With Composite of Adjudicated Major Bleeding and Adjudicated Clinically Relevant Non-major (CRNM) Bleeding During the Treatment Period at 90 days. Started Apr 2016; status: completed.